Comment on “Doing the math: A simple approach to topical timolol dosing for infantile hemangiomas”

Hill, India; Stefanko, Nicole; Drolet, Beth A.

doi:10.1111/pde.13577

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ariwibowo, Danarti et al and associates found that Timolol maleate 0.5% the answer was better than corticosteroids in reducing the dimensions of superficial IH. 10,14,[17][18][19][20][21][22][23][24] Our study also showed reduction in size,colour and shape of superficial infantile hemangiomas in approximately 08-12 weeks after the initiation of treatment.…”

Section: A H E a D O F P R I N Tsupporting

confidence: 68%

Role of topical beta blockers in regression of infantile capillary hemangioma

Junejo

Rebecca²,

Memon³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To observe efficacy of Timolol maleate 0.5% by topical and surface application in infantile superficial capillary hemangioma of eyelid. Methods: This multi-centered clinical case series was carried out at Ophthalmology Department of Bilawal Medical College and Institute of Ophthalmology, LUMHS, Jamshoro from November 2019 to May 2020. We included 14 subjects. All the patients were subjected to detailed clinical examination. Before starting the topical beta blockers, the enrolled subjects had obtained the expert opinion by pediatrician to rule out any preexisting developmental cardio vascular disease. Topical beta blockers 0.5% drops were thus started with, against the ongoing finding of superficial capillary hemangioma of eyelid. Results: There was significant regression in size of infantile hemangioma after treating with topical timolol maleate 0.5%. We included 14 subjects in this study. Mean±SD age of patients was 4.94. Complete regression was seen in 08 subjects at the end of 12 weeks (64%) while 03 were completely cured at 08 weeks (21%) and 01 patient lost follow up with us. No significant ocular and systemic side effects were noted. Conclusion: Topical timolol maleate 0.5% can be the first-line treatment modality for superficial capillary hemangiomas due to its better safety and efficacy. doi: https://doi.org/10.12669/pjms.37.7.4317 How to cite this:Junejo MS, Rebecca, Memon MN, Shaikh SP. Role of topical beta blockers in regression of infantile capillary hemangioma. Pak J Med Sci. 2021;37(7):---------. doi: https://doi.org/10.12669/pjms.37.7.4317 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: A H E a D O F P R I N Tsupporting

confidence: 68%

Role of topical beta blockers in regression of infantile capillary hemangioma

Junejo

Rebecca²,

Memon³

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…However, even at the small doses typically used to treat IH, timolol has been detected in infants’ blood and urine. A recent study of 43 infants treated with two drops of topical timolol 0.5% gel‐forming solution daily found detectable plasma levels in 90% of infants . A second prospective study of 26 infants treated with topical timolol for IH found that 38% had detectable plasma levels, although none exhibited drug‐related side effects .…”

Section: Introductionmentioning

confidence: 99%

Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas

Mannschreck

Huang

Lie

et al. 2019

Pediatric Dermatology

View full text Add to dashboard Cite

Background/Objectives: First-line therapy for infantile hemangiomas (IH) is oral propranolol, a systemic beta-blocker with the risk of rare but serious adverse effects.Topical timolol presents an attractive off-label alternative with good tolerability, but sequential therapy with propranolol followed by timolol is not well studied. Here, we report effects of topical timolol preceding or following oral propranolol as adjunct therapy for IH. Methods:A retrospective chart review of 559 patients with IH seen at the pediatric dermatology clinic of a tertiary care center between December 2008 and January 2018. Children were grouped by treatment received: propranolol only, timolol only, propranolol to timolol, timolol to propranolol to timolol, and timolol to propranolol.Patient demographics, clinical/treatment characteristics, and pairwise differences were explored between groups. Results:Among all patients treated with propranolol, those who received propranolol followed by timolol received the shortest duration of oral propranolol and were the youngest at the time of propranolol completion. These patients received propranolol for a median of 2.2 months duration (P = 0.006) and were a median of 1.7 months younger (P = 0.007) compared with patients who received oral propranolol only. None had treatment failure defined as requiring propranolol reinitiation, compared with 13% of patients in the propranolol only group (P = 0.036). Conclusions:Sequential therapy with oral propranolol followed by topical timolol for IH may help minimize potential adverse effects of systemic beta-blockers by reducing the duration of propranolol therapy and facilitating successful taper at a younger age without an increase in treatment failures. K E Y W O R D S infantile hemangioma, propranolol, timolol Pediatric Dermatology MANNSCHRECK Et Al.

show abstract